TITLE

Akorn Acquires Eye Drugs From Merck; Stock Hits High

AUTHOR(S)
AMY REEVES
PUB. DATE
November 2013
SOURCE
Investors Business Daily;11/15/2013, p00
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
Drugmaker
ACCESSION #
91992233

 

Related Articles

  • Merck and Schering-Plough to merge.  // TCE: The Chemical Engineer;Apr2009, Issue 814, p5 

    The article deals with the decision of Merck & Co. to pay $41 billion to acquire pharmaceutical firm Schering-Plough. The boards of both companies have approved the offer, which is a 34 percent premium on the March 6, 2009 share price of Schering-Plough. An annual cost-savings of $3.5 billion is...

  • Merck Purchases Aton Pharma To Expand Its Cancer Drug Pipeline.  // Chemical Market Reporter;3/1/2004, Vol. 265 Issue 9, p3 

    Reports on Merck & Co. Inc.'s acquisition of Aton Pharma Inc., an anticancer drug developer in the U.S.

  • Merck Eyes 'Strong Start'.  // Chain Drug Review;11/23/2009, Vol. 31 Issue 20, p43 

    The article reports on the acquisition of Schering-Plough Corp by Merck & Co. Inc. which has became the world's second-largest drug manufacturer following Pfizer Inc. Richard Clark, chief executive officer of Merck, mentions that the acquisition has placed the company to be ready in delivering...

  • Merck strengthens drug pipeline in rival takeover.  // Nature;3/12/2009, Vol. 458 Issue 7235, p137 

    The article discusses the acquisition by the of U.S. pharmaceutical company Merck of its rival Schering-Plough in a deal which was unanimously approved by the boards of both companies. The decision is viewed as a way to protect Merck's drug-development pipeline. The new company will called by...

  • Merck swoops in on Schering-Plough.  // Pharmaceutical Technology Europe;Apr2009, Vol. 21 Issue 4, p8 

    The article reports on the merger agreement between Merck and Co. Inc. and Schering-Plough Corp. to create a new pharmaceutical giant. Furthermore, it notes that the move will expand Merck's portfolio of medicines and will double the number of potential medicines that the company has in the...

  • Major players make move from competing to combining. DeArment, Alaric // Drug Store News;5/25/2009, Vol. 31 Issue 6, p54 

    The article reports on the growth of pharmaceutical companies engaging into merger and acquisition. It reveals that the move aims to enhance the operations and competitiveness of companies in times of the economic crisis, which include Pfizer Inc., Merck & Co., and GlaxoSmithKline. In addition,...

  • Merck, Schering-Plough Planning to Merge.  // Bioworld Week;3/16/2009, Vol. 17 Issue 11, p3 

    The article reports on the merger plan of Merck & Co. Inc. and Schering-Plough Corp. It states that a future cash-and-stock deal between two giant companies is likely to happen considering the alleged adverse effects of economic woes of the U.S. on them. If completed, the merger is expected to...

  • Merck & Co. to Acquire Schering-Plough for $41 billion. Ramesh, Deepti // Chemical Week;3/16/2009, Vol. 171 Issue 8, p43 

    The article reports on the decision of Merck & Co. to acquire Schering-Plough. The deal, estimated at $41.1 billion in stock and cash, will create a megapharma company with combined sales of $47 billion. Under the agreement, Schering-Plough shareholders will receive 0.5767 shares and $10.50 in...

  • Ridaforolimus Combo Data, Buyout Rumors Boost Ariad. Morrison, Trista // BioWorld Today;7/29/2009, Vol. 20 Issue 144, p1 

    The article reports on the 14% increase in the shares of Ariad Pharmaceuticals Inc. on July 28, 2009. This took place following the released preliminary data from two earl stage trials combining ridaforolimus with other targeted cancer drugs in treatment-resistant patients. The ridaforolimus...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics